Global Poliomyelitis Vaccine research

Poliomyelitis Vaccine Comprehensive Study by Type (Oral Polio Vaccine (OPV), Inactivated Poliomyelitis Vaccine (IPV)), Application (Hospital, Clinics, Public Services, Others), Route of Administration (Oral, Injection), Poliomyelitis Type (Type 1, Type 2, Type 3) Players and Region - Global Market Outlook to 2026

Poliomyelitis Vaccine Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Poliomyelitis Vaccine Market Scope?
Poliomyelitis is a highly infectious viral disease caused by poliovirus that invades the human nervous system, causing severe life-threatening disability and irreversible paralysis. Poliomyelitis is considered an acute communicable disease caused by human enteroviruses of the Picornaviridae family. Polioviruses may spread by stool-to-mouth or mouth-to-mouth routes due to poor hygiene and personal hygiene. Polio vaccines like the oral polio vaccine (OPV) and the inactivated poliomyelitis vaccine (IPV) are being developed to immunize children against polio. The OPV contains attenuated live strains of such viruses and the IPV contains three poliovirus strains, Mahoney Type 1, MEF-1 (Middle East Forces) Type 2, and Saukett Type 3. OPV is given by the oral route while the IPV is given by the injectable route. It can be prevented by the polio vaccine.

The Poliomyelitis Vaccine market study is being classified by Type (Oral Polio Vaccine (OPV) and Inactivated Poliomyelitis Vaccine (IPV)), by Application (Hospital, Clinics, Public Services and Others) and major geographies with country level break-up.

There are relatively a few vaccine manufacturers that meet the international standards, due to which an individual vaccine manufacturer, the market becomes monopolies or oligopoly either by the means of product or presentation. Very, few suppliers and production capacities lead to a tenuous balance between demand and supply in many individual vaccine markets. Analysts at AMA predicts that Players from Asian will contribute to the maximum growth of Global Poliomyelitis Vaccine market throughout the predicted period.

Sanofi (France), GSK (United Kingdom), Bibcol (India), Crucell (Johnson & Johnson) (Netherlands), Serum Institute (India), Merck & Co. (United States), Tiantan Biological (China), Panacea Biotec Ltd. (India), Bio-Med (India), Halfkin Bio-Pharmaceuticals Corporation Ltd. (India) and China National Biotech Group (China) are some of the key players profiled in the study.

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Poliomyelitis Vaccine market by Type, Application and Region.

On the basis of geography, the market of Poliomyelitis Vaccine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).


WHO ensures the safety and quality of vaccines and works closely on global standards which are developed and made readily available. WHO provides norms and standard and give advice to procurement agencies and countries on the acceptability, in the principle of vaccines. It has also established the Global Advisory Committee on vaccine safety which includes national experts and authority to support vaccine safety.

Influencing Market Trend
  • A Rise in Rigorous Monitoring and Effective Communication
  • Growth in Skilled and Motivated Staff, And Adequate Funding
  • A Rise in Ensuring Vaccination in Conflict Zones and Countries with Weak Health Systems

Market Drivers
  • High Prevalence of Poliomyelitis
  • The Increased Patient Awareness Level
  • High Focus on Immunization Program around the Globe
  • Increasing Efforts for Vaccination Led By the WHO and UNICEF

Opportunities
  • Emerging Markets and Huge Investment in Research and Development
  • High Prevalence of Poliomyelitis and Strong Immunization Programme by Government

Restraints
  • Complicated Regulatory Scenario

Challenges
  • High Cost Involved in Poliomyelitis Vaccine Development


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Providers of Poliomyelitis Vaccine, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Report Objectives / Segmentation Covered

By Type
  • Oral Polio Vaccine (OPV)
  • Inactivated Poliomyelitis Vaccine (IPV)
By Application
  • Hospital
  • Clinics
  • Public Services
  • Others
By Route of Administration
  • Oral
  • Injection

By Poliomyelitis Type
  • Type 1
  • Type 2
  • Type 3

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. High Prevalence of Poliomyelitis
      • 3.2.2. The Increased Patient Awareness Level
      • 3.2.3. High Focus on Immunization Program around the Globe
      • 3.2.4. Increasing Efforts for Vaccination Led By the WHO and UNICEF
    • 3.3. Market Challenges
      • 3.3.1. High Cost Involved in Poliomyelitis Vaccine Development
    • 3.4. Market Trends
      • 3.4.1. A Rise in Rigorous Monitoring and Effective Communication
      • 3.4.2. Growth in Skilled and Motivated Staff, And Adequate Funding
      • 3.4.3. A Rise in Ensuring Vaccination in Conflict Zones and Countries with Weak Health Systems
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Poliomyelitis Vaccine, by Type, Application, Route of Administration, Poliomyelitis Type and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Poliomyelitis Vaccine (Value)
      • 5.2.1. Global Poliomyelitis Vaccine by: Type (Value)
        • 5.2.1.1. Oral Polio Vaccine (OPV)
        • 5.2.1.2. Inactivated Poliomyelitis Vaccine (IPV)
      • 5.2.2. Global Poliomyelitis Vaccine by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Clinics
        • 5.2.2.3. Public Services
        • 5.2.2.4. Others
      • 5.2.3. Global Poliomyelitis Vaccine by: Route of Administration (Value)
        • 5.2.3.1. Oral
        • 5.2.3.2. Injection
      • 5.2.4. Global Poliomyelitis Vaccine by: Poliomyelitis Type (Value)
        • 5.2.4.1. Type 1
        • 5.2.4.2. Type 2
        • 5.2.4.3. Type 3
      • 5.2.5. Global Poliomyelitis Vaccine Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Poliomyelitis Vaccine (Volume)
      • 5.3.1. Global Poliomyelitis Vaccine by: Type (Volume)
        • 5.3.1.1. Oral Polio Vaccine (OPV)
        • 5.3.1.2. Inactivated Poliomyelitis Vaccine (IPV)
      • 5.3.2. Global Poliomyelitis Vaccine by: Application (Volume)
        • 5.3.2.1. Hospital
        • 5.3.2.2. Clinics
        • 5.3.2.3. Public Services
        • 5.3.2.4. Others
      • 5.3.3. Global Poliomyelitis Vaccine by: Route of Administration (Volume)
        • 5.3.3.1. Oral
        • 5.3.3.2. Injection
      • 5.3.4. Global Poliomyelitis Vaccine by: Poliomyelitis Type (Volume)
        • 5.3.4.1. Type 1
        • 5.3.4.2. Type 2
        • 5.3.4.3. Type 3
      • 5.3.5. Global Poliomyelitis Vaccine Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Poliomyelitis Vaccine (Price)
      • 5.4.1. Global Poliomyelitis Vaccine by: Type (Price)
  • 6. Poliomyelitis Vaccine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Sanofi (France)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GSK (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Bibcol (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Crucell (Johnson & Johnson) (Netherlands)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Serum Institute (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Merck & Co. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Tiantan Biological (China)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Panacea Biotec Ltd. (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Bio-Med (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Halfkin Bio-Pharmaceuticals Corporation Ltd. (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. China National Biotech Group (China)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Poliomyelitis Vaccine Sale, by Type, Application, Route of Administration, Poliomyelitis Type and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Poliomyelitis Vaccine (Value)
      • 7.2.1. Global Poliomyelitis Vaccine by: Type (Value)
        • 7.2.1.1. Oral Polio Vaccine (OPV)
        • 7.2.1.2. Inactivated Poliomyelitis Vaccine (IPV)
      • 7.2.2. Global Poliomyelitis Vaccine by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Clinics
        • 7.2.2.3. Public Services
        • 7.2.2.4. Others
      • 7.2.3. Global Poliomyelitis Vaccine by: Route of Administration (Value)
        • 7.2.3.1. Oral
        • 7.2.3.2. Injection
      • 7.2.4. Global Poliomyelitis Vaccine by: Poliomyelitis Type (Value)
        • 7.2.4.1. Type 1
        • 7.2.4.2. Type 2
        • 7.2.4.3. Type 3
      • 7.2.5. Global Poliomyelitis Vaccine Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Poliomyelitis Vaccine (Volume)
      • 7.3.1. Global Poliomyelitis Vaccine by: Type (Volume)
        • 7.3.1.1. Oral Polio Vaccine (OPV)
        • 7.3.1.2. Inactivated Poliomyelitis Vaccine (IPV)
      • 7.3.2. Global Poliomyelitis Vaccine by: Application (Volume)
        • 7.3.2.1. Hospital
        • 7.3.2.2. Clinics
        • 7.3.2.3. Public Services
        • 7.3.2.4. Others
      • 7.3.3. Global Poliomyelitis Vaccine by: Route of Administration (Volume)
        • 7.3.3.1. Oral
        • 7.3.3.2. Injection
      • 7.3.4. Global Poliomyelitis Vaccine by: Poliomyelitis Type (Volume)
        • 7.3.4.1. Type 1
        • 7.3.4.2. Type 2
        • 7.3.4.3. Type 3
      • 7.3.5. Global Poliomyelitis Vaccine Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Poliomyelitis Vaccine (Price)
      • 7.4.1. Global Poliomyelitis Vaccine by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Poliomyelitis Vaccine: by Type(USD Million)
  • Table 2. Poliomyelitis Vaccine Oral Polio Vaccine (OPV) , by Region USD Million (2015-2020)
  • Table 3. Poliomyelitis Vaccine Inactivated Poliomyelitis Vaccine (IPV) , by Region USD Million (2015-2020)
  • Table 4. Poliomyelitis Vaccine: by Application(USD Million)
  • Table 5. Poliomyelitis Vaccine Hospital , by Region USD Million (2015-2020)
  • Table 6. Poliomyelitis Vaccine Clinics , by Region USD Million (2015-2020)
  • Table 7. Poliomyelitis Vaccine Public Services , by Region USD Million (2015-2020)
  • Table 8. Poliomyelitis Vaccine Others , by Region USD Million (2015-2020)
  • Table 9. Poliomyelitis Vaccine: by Route of Administration(USD Million)
  • Table 10. Poliomyelitis Vaccine Oral , by Region USD Million (2015-2020)
  • Table 11. Poliomyelitis Vaccine Injection , by Region USD Million (2015-2020)
  • Table 12. Poliomyelitis Vaccine: by Poliomyelitis Type(USD Million)
  • Table 13. Poliomyelitis Vaccine Type 1 , by Region USD Million (2015-2020)
  • Table 14. Poliomyelitis Vaccine Type 2 , by Region USD Million (2015-2020)
  • Table 15. Poliomyelitis Vaccine Type 3 , by Region USD Million (2015-2020)
  • Table 16. South America Poliomyelitis Vaccine, by Country USD Million (2015-2020)
  • Table 17. South America Poliomyelitis Vaccine, by Type USD Million (2015-2020)
  • Table 18. South America Poliomyelitis Vaccine, by Application USD Million (2015-2020)
  • Table 19. South America Poliomyelitis Vaccine, by Route of Administration USD Million (2015-2020)
  • Table 20. South America Poliomyelitis Vaccine, by Poliomyelitis Type USD Million (2015-2020)
  • Table 21. Brazil Poliomyelitis Vaccine, by Type USD Million (2015-2020)
  • Table 22. Brazil Poliomyelitis Vaccine, by Application USD Million (2015-2020)
  • Table 23. Brazil Poliomyelitis Vaccine, by Route of Administration USD Million (2015-2020)
  • Table 24. Brazil Poliomyelitis Vaccine, by Poliomyelitis Type USD Million (2015-2020)
  • Table 25. Argentina Poliomyelitis Vaccine, by Type USD Million (2015-2020)
  • Table 26. Argentina Poliomyelitis Vaccine, by Application USD Million (2015-2020)
  • Table 27. Argentina Poliomyelitis Vaccine, by Route of Administration USD Million (2015-2020)
  • Table 28. Argentina Poliomyelitis Vaccine, by Poliomyelitis Type USD Million (2015-2020)
  • Table 29. Rest of South America Poliomyelitis Vaccine, by Type USD Million (2015-2020)
  • Table 30. Rest of South America Poliomyelitis Vaccine, by Application USD Million (2015-2020)
  • Table 31. Rest of South America Poliomyelitis Vaccine, by Route of Administration USD Million (2015-2020)
  • Table 32. Rest of South America Poliomyelitis Vaccine, by Poliomyelitis Type USD Million (2015-2020)
  • Table 33. Asia Pacific Poliomyelitis Vaccine, by Country USD Million (2015-2020)
  • Table 34. Asia Pacific Poliomyelitis Vaccine, by Type USD Million (2015-2020)
  • Table 35. Asia Pacific Poliomyelitis Vaccine, by Application USD Million (2015-2020)
  • Table 36. Asia Pacific Poliomyelitis Vaccine, by Route of Administration USD Million (2015-2020)
  • Table 37. Asia Pacific Poliomyelitis Vaccine, by Poliomyelitis Type USD Million (2015-2020)
  • Table 38. China Poliomyelitis Vaccine, by Type USD Million (2015-2020)
  • Table 39. China Poliomyelitis Vaccine, by Application USD Million (2015-2020)
  • Table 40. China Poliomyelitis Vaccine, by Route of Administration USD Million (2015-2020)
  • Table 41. China Poliomyelitis Vaccine, by Poliomyelitis Type USD Million (2015-2020)
  • Table 42. Japan Poliomyelitis Vaccine, by Type USD Million (2015-2020)
  • Table 43. Japan Poliomyelitis Vaccine, by Application USD Million (2015-2020)
  • Table 44. Japan Poliomyelitis Vaccine, by Route of Administration USD Million (2015-2020)
  • Table 45. Japan Poliomyelitis Vaccine, by Poliomyelitis Type USD Million (2015-2020)
  • Table 46. India Poliomyelitis Vaccine, by Type USD Million (2015-2020)
  • Table 47. India Poliomyelitis Vaccine, by Application USD Million (2015-2020)
  • Table 48. India Poliomyelitis Vaccine, by Route of Administration USD Million (2015-2020)
  • Table 49. India Poliomyelitis Vaccine, by Poliomyelitis Type USD Million (2015-2020)
  • Table 50. South Korea Poliomyelitis Vaccine, by Type USD Million (2015-2020)
  • Table 51. South Korea Poliomyelitis Vaccine, by Application USD Million (2015-2020)
  • Table 52. South Korea Poliomyelitis Vaccine, by Route of Administration USD Million (2015-2020)
  • Table 53. South Korea Poliomyelitis Vaccine, by Poliomyelitis Type USD Million (2015-2020)
  • Table 54. Taiwan Poliomyelitis Vaccine, by Type USD Million (2015-2020)
  • Table 55. Taiwan Poliomyelitis Vaccine, by Application USD Million (2015-2020)
  • Table 56. Taiwan Poliomyelitis Vaccine, by Route of Administration USD Million (2015-2020)
  • Table 57. Taiwan Poliomyelitis Vaccine, by Poliomyelitis Type USD Million (2015-2020)
  • Table 58. Australia Poliomyelitis Vaccine, by Type USD Million (2015-2020)
  • Table 59. Australia Poliomyelitis Vaccine, by Application USD Million (2015-2020)
  • Table 60. Australia Poliomyelitis Vaccine, by Route of Administration USD Million (2015-2020)
  • Table 61. Australia Poliomyelitis Vaccine, by Poliomyelitis Type USD Million (2015-2020)
  • Table 62. Rest of Asia-Pacific Poliomyelitis Vaccine, by Type USD Million (2015-2020)
  • Table 63. Rest of Asia-Pacific Poliomyelitis Vaccine, by Application USD Million (2015-2020)
  • Table 64. Rest of Asia-Pacific Poliomyelitis Vaccine, by Route of Administration USD Million (2015-2020)
  • Table 65. Rest of Asia-Pacific Poliomyelitis Vaccine, by Poliomyelitis Type USD Million (2015-2020)
  • Table 66. Europe Poliomyelitis Vaccine, by Country USD Million (2015-2020)
  • Table 67. Europe Poliomyelitis Vaccine, by Type USD Million (2015-2020)
  • Table 68. Europe Poliomyelitis Vaccine, by Application USD Million (2015-2020)
  • Table 69. Europe Poliomyelitis Vaccine, by Route of Administration USD Million (2015-2020)
  • Table 70. Europe Poliomyelitis Vaccine, by Poliomyelitis Type USD Million (2015-2020)
  • Table 71. Germany Poliomyelitis Vaccine, by Type USD Million (2015-2020)
  • Table 72. Germany Poliomyelitis Vaccine, by Application USD Million (2015-2020)
  • Table 73. Germany Poliomyelitis Vaccine, by Route of Administration USD Million (2015-2020)
  • Table 74. Germany Poliomyelitis Vaccine, by Poliomyelitis Type USD Million (2015-2020)
  • Table 75. France Poliomyelitis Vaccine, by Type USD Million (2015-2020)
  • Table 76. France Poliomyelitis Vaccine, by Application USD Million (2015-2020)
  • Table 77. France Poliomyelitis Vaccine, by Route of Administration USD Million (2015-2020)
  • Table 78. France Poliomyelitis Vaccine, by Poliomyelitis Type USD Million (2015-2020)
  • Table 79. Italy Poliomyelitis Vaccine, by Type USD Million (2015-2020)
  • Table 80. Italy Poliomyelitis Vaccine, by Application USD Million (2015-2020)
  • Table 81. Italy Poliomyelitis Vaccine, by Route of Administration USD Million (2015-2020)
  • Table 82. Italy Poliomyelitis Vaccine, by Poliomyelitis Type USD Million (2015-2020)
  • Table 83. United Kingdom Poliomyelitis Vaccine, by Type USD Million (2015-2020)
  • Table 84. United Kingdom Poliomyelitis Vaccine, by Application USD Million (2015-2020)
  • Table 85. United Kingdom Poliomyelitis Vaccine, by Route of Administration USD Million (2015-2020)
  • Table 86. United Kingdom Poliomyelitis Vaccine, by Poliomyelitis Type USD Million (2015-2020)
  • Table 87. Netherlands Poliomyelitis Vaccine, by Type USD Million (2015-2020)
  • Table 88. Netherlands Poliomyelitis Vaccine, by Application USD Million (2015-2020)
  • Table 89. Netherlands Poliomyelitis Vaccine, by Route of Administration USD Million (2015-2020)
  • Table 90. Netherlands Poliomyelitis Vaccine, by Poliomyelitis Type USD Million (2015-2020)
  • Table 91. Rest of Europe Poliomyelitis Vaccine, by Type USD Million (2015-2020)
  • Table 92. Rest of Europe Poliomyelitis Vaccine, by Application USD Million (2015-2020)
  • Table 93. Rest of Europe Poliomyelitis Vaccine, by Route of Administration USD Million (2015-2020)
  • Table 94. Rest of Europe Poliomyelitis Vaccine, by Poliomyelitis Type USD Million (2015-2020)
  • Table 95. MEA Poliomyelitis Vaccine, by Country USD Million (2015-2020)
  • Table 96. MEA Poliomyelitis Vaccine, by Type USD Million (2015-2020)
  • Table 97. MEA Poliomyelitis Vaccine, by Application USD Million (2015-2020)
  • Table 98. MEA Poliomyelitis Vaccine, by Route of Administration USD Million (2015-2020)
  • Table 99. MEA Poliomyelitis Vaccine, by Poliomyelitis Type USD Million (2015-2020)
  • Table 100. Middle East Poliomyelitis Vaccine, by Type USD Million (2015-2020)
  • Table 101. Middle East Poliomyelitis Vaccine, by Application USD Million (2015-2020)
  • Table 102. Middle East Poliomyelitis Vaccine, by Route of Administration USD Million (2015-2020)
  • Table 103. Middle East Poliomyelitis Vaccine, by Poliomyelitis Type USD Million (2015-2020)
  • Table 104. Africa Poliomyelitis Vaccine, by Type USD Million (2015-2020)
  • Table 105. Africa Poliomyelitis Vaccine, by Application USD Million (2015-2020)
  • Table 106. Africa Poliomyelitis Vaccine, by Route of Administration USD Million (2015-2020)
  • Table 107. Africa Poliomyelitis Vaccine, by Poliomyelitis Type USD Million (2015-2020)
  • Table 108. North America Poliomyelitis Vaccine, by Country USD Million (2015-2020)
  • Table 109. North America Poliomyelitis Vaccine, by Type USD Million (2015-2020)
  • Table 110. North America Poliomyelitis Vaccine, by Application USD Million (2015-2020)
  • Table 111. North America Poliomyelitis Vaccine, by Route of Administration USD Million (2015-2020)
  • Table 112. North America Poliomyelitis Vaccine, by Poliomyelitis Type USD Million (2015-2020)
  • Table 113. United States Poliomyelitis Vaccine, by Type USD Million (2015-2020)
  • Table 114. United States Poliomyelitis Vaccine, by Application USD Million (2015-2020)
  • Table 115. United States Poliomyelitis Vaccine, by Route of Administration USD Million (2015-2020)
  • Table 116. United States Poliomyelitis Vaccine, by Poliomyelitis Type USD Million (2015-2020)
  • Table 117. Canada Poliomyelitis Vaccine, by Type USD Million (2015-2020)
  • Table 118. Canada Poliomyelitis Vaccine, by Application USD Million (2015-2020)
  • Table 119. Canada Poliomyelitis Vaccine, by Route of Administration USD Million (2015-2020)
  • Table 120. Canada Poliomyelitis Vaccine, by Poliomyelitis Type USD Million (2015-2020)
  • Table 121. Mexico Poliomyelitis Vaccine, by Type USD Million (2015-2020)
  • Table 122. Mexico Poliomyelitis Vaccine, by Application USD Million (2015-2020)
  • Table 123. Mexico Poliomyelitis Vaccine, by Route of Administration USD Million (2015-2020)
  • Table 124. Mexico Poliomyelitis Vaccine, by Poliomyelitis Type USD Million (2015-2020)
  • Table 125. Poliomyelitis Vaccine Sales: by Type(K Units)
  • Table 126. Poliomyelitis Vaccine Sales Oral Polio Vaccine (OPV) , by Region K Units (2015-2020)
  • Table 127. Poliomyelitis Vaccine Sales Inactivated Poliomyelitis Vaccine (IPV) , by Region K Units (2015-2020)
  • Table 128. Poliomyelitis Vaccine Sales: by Application(K Units)
  • Table 129. Poliomyelitis Vaccine Sales Hospital , by Region K Units (2015-2020)
  • Table 130. Poliomyelitis Vaccine Sales Clinics , by Region K Units (2015-2020)
  • Table 131. Poliomyelitis Vaccine Sales Public Services , by Region K Units (2015-2020)
  • Table 132. Poliomyelitis Vaccine Sales Others , by Region K Units (2015-2020)
  • Table 133. Poliomyelitis Vaccine Sales: by Route of Administration(K Units)
  • Table 134. Poliomyelitis Vaccine Sales Oral , by Region K Units (2015-2020)
  • Table 135. Poliomyelitis Vaccine Sales Injection , by Region K Units (2015-2020)
  • Table 136. Poliomyelitis Vaccine Sales: by Poliomyelitis Type(K Units)
  • Table 137. Poliomyelitis Vaccine Sales Type 1 , by Region K Units (2015-2020)
  • Table 138. Poliomyelitis Vaccine Sales Type 2 , by Region K Units (2015-2020)
  • Table 139. Poliomyelitis Vaccine Sales Type 3 , by Region K Units (2015-2020)
  • Table 140. South America Poliomyelitis Vaccine Sales, by Country K Units (2015-2020)
  • Table 141. South America Poliomyelitis Vaccine Sales, by Type K Units (2015-2020)
  • Table 142. South America Poliomyelitis Vaccine Sales, by Application K Units (2015-2020)
  • Table 143. South America Poliomyelitis Vaccine Sales, by Route of Administration K Units (2015-2020)
  • Table 144. South America Poliomyelitis Vaccine Sales, by Poliomyelitis Type K Units (2015-2020)
  • Table 145. Brazil Poliomyelitis Vaccine Sales, by Type K Units (2015-2020)
  • Table 146. Brazil Poliomyelitis Vaccine Sales, by Application K Units (2015-2020)
  • Table 147. Brazil Poliomyelitis Vaccine Sales, by Route of Administration K Units (2015-2020)
  • Table 148. Brazil Poliomyelitis Vaccine Sales, by Poliomyelitis Type K Units (2015-2020)
  • Table 149. Argentina Poliomyelitis Vaccine Sales, by Type K Units (2015-2020)
  • Table 150. Argentina Poliomyelitis Vaccine Sales, by Application K Units (2015-2020)
  • Table 151. Argentina Poliomyelitis Vaccine Sales, by Route of Administration K Units (2015-2020)
  • Table 152. Argentina Poliomyelitis Vaccine Sales, by Poliomyelitis Type K Units (2015-2020)
  • Table 153. Rest of South America Poliomyelitis Vaccine Sales, by Type K Units (2015-2020)
  • Table 154. Rest of South America Poliomyelitis Vaccine Sales, by Application K Units (2015-2020)
  • Table 155. Rest of South America Poliomyelitis Vaccine Sales, by Route of Administration K Units (2015-2020)
  • Table 156. Rest of South America Poliomyelitis Vaccine Sales, by Poliomyelitis Type K Units (2015-2020)
  • Table 157. Asia Pacific Poliomyelitis Vaccine Sales, by Country K Units (2015-2020)
  • Table 158. Asia Pacific Poliomyelitis Vaccine Sales, by Type K Units (2015-2020)
  • Table 159. Asia Pacific Poliomyelitis Vaccine Sales, by Application K Units (2015-2020)
  • Table 160. Asia Pacific Poliomyelitis Vaccine Sales, by Route of Administration K Units (2015-2020)
  • Table 161. Asia Pacific Poliomyelitis Vaccine Sales, by Poliomyelitis Type K Units (2015-2020)
  • Table 162. China Poliomyelitis Vaccine Sales, by Type K Units (2015-2020)
  • Table 163. China Poliomyelitis Vaccine Sales, by Application K Units (2015-2020)
  • Table 164. China Poliomyelitis Vaccine Sales, by Route of Administration K Units (2015-2020)
  • Table 165. China Poliomyelitis Vaccine Sales, by Poliomyelitis Type K Units (2015-2020)
  • Table 166. Japan Poliomyelitis Vaccine Sales, by Type K Units (2015-2020)
  • Table 167. Japan Poliomyelitis Vaccine Sales, by Application K Units (2015-2020)
  • Table 168. Japan Poliomyelitis Vaccine Sales, by Route of Administration K Units (2015-2020)
  • Table 169. Japan Poliomyelitis Vaccine Sales, by Poliomyelitis Type K Units (2015-2020)
  • Table 170. India Poliomyelitis Vaccine Sales, by Type K Units (2015-2020)
  • Table 171. India Poliomyelitis Vaccine Sales, by Application K Units (2015-2020)
  • Table 172. India Poliomyelitis Vaccine Sales, by Route of Administration K Units (2015-2020)
  • Table 173. India Poliomyelitis Vaccine Sales, by Poliomyelitis Type K Units (2015-2020)
  • Table 174. South Korea Poliomyelitis Vaccine Sales, by Type K Units (2015-2020)
  • Table 175. South Korea Poliomyelitis Vaccine Sales, by Application K Units (2015-2020)
  • Table 176. South Korea Poliomyelitis Vaccine Sales, by Route of Administration K Units (2015-2020)
  • Table 177. South Korea Poliomyelitis Vaccine Sales, by Poliomyelitis Type K Units (2015-2020)
  • Table 178. Taiwan Poliomyelitis Vaccine Sales, by Type K Units (2015-2020)
  • Table 179. Taiwan Poliomyelitis Vaccine Sales, by Application K Units (2015-2020)
  • Table 180. Taiwan Poliomyelitis Vaccine Sales, by Route of Administration K Units (2015-2020)
  • Table 181. Taiwan Poliomyelitis Vaccine Sales, by Poliomyelitis Type K Units (2015-2020)
  • Table 182. Australia Poliomyelitis Vaccine Sales, by Type K Units (2015-2020)
  • Table 183. Australia Poliomyelitis Vaccine Sales, by Application K Units (2015-2020)
  • Table 184. Australia Poliomyelitis Vaccine Sales, by Route of Administration K Units (2015-2020)
  • Table 185. Australia Poliomyelitis Vaccine Sales, by Poliomyelitis Type K Units (2015-2020)
  • Table 186. Rest of Asia-Pacific Poliomyelitis Vaccine Sales, by Type K Units (2015-2020)
  • Table 187. Rest of Asia-Pacific Poliomyelitis Vaccine Sales, by Application K Units (2015-2020)
  • Table 188. Rest of Asia-Pacific Poliomyelitis Vaccine Sales, by Route of Administration K Units (2015-2020)
  • Table 189. Rest of Asia-Pacific Poliomyelitis Vaccine Sales, by Poliomyelitis Type K Units (2015-2020)
  • Table 190. Europe Poliomyelitis Vaccine Sales, by Country K Units (2015-2020)
  • Table 191. Europe Poliomyelitis Vaccine Sales, by Type K Units (2015-2020)
  • Table 192. Europe Poliomyelitis Vaccine Sales, by Application K Units (2015-2020)
  • Table 193. Europe Poliomyelitis Vaccine Sales, by Route of Administration K Units (2015-2020)
  • Table 194. Europe Poliomyelitis Vaccine Sales, by Poliomyelitis Type K Units (2015-2020)
  • Table 195. Germany Poliomyelitis Vaccine Sales, by Type K Units (2015-2020)
  • Table 196. Germany Poliomyelitis Vaccine Sales, by Application K Units (2015-2020)
  • Table 197. Germany Poliomyelitis Vaccine Sales, by Route of Administration K Units (2015-2020)
  • Table 198. Germany Poliomyelitis Vaccine Sales, by Poliomyelitis Type K Units (2015-2020)
  • Table 199. France Poliomyelitis Vaccine Sales, by Type K Units (2015-2020)
  • Table 200. France Poliomyelitis Vaccine Sales, by Application K Units (2015-2020)
  • Table 201. France Poliomyelitis Vaccine Sales, by Route of Administration K Units (2015-2020)
  • Table 202. France Poliomyelitis Vaccine Sales, by Poliomyelitis Type K Units (2015-2020)
  • Table 203. Italy Poliomyelitis Vaccine Sales, by Type K Units (2015-2020)
  • Table 204. Italy Poliomyelitis Vaccine Sales, by Application K Units (2015-2020)
  • Table 205. Italy Poliomyelitis Vaccine Sales, by Route of Administration K Units (2015-2020)
  • Table 206. Italy Poliomyelitis Vaccine Sales, by Poliomyelitis Type K Units (2015-2020)
  • Table 207. United Kingdom Poliomyelitis Vaccine Sales, by Type K Units (2015-2020)
  • Table 208. United Kingdom Poliomyelitis Vaccine Sales, by Application K Units (2015-2020)
  • Table 209. United Kingdom Poliomyelitis Vaccine Sales, by Route of Administration K Units (2015-2020)
  • Table 210. United Kingdom Poliomyelitis Vaccine Sales, by Poliomyelitis Type K Units (2015-2020)
  • Table 211. Netherlands Poliomyelitis Vaccine Sales, by Type K Units (2015-2020)
  • Table 212. Netherlands Poliomyelitis Vaccine Sales, by Application K Units (2015-2020)
  • Table 213. Netherlands Poliomyelitis Vaccine Sales, by Route of Administration K Units (2015-2020)
  • Table 214. Netherlands Poliomyelitis Vaccine Sales, by Poliomyelitis Type K Units (2015-2020)
  • Table 215. Rest of Europe Poliomyelitis Vaccine Sales, by Type K Units (2015-2020)
  • Table 216. Rest of Europe Poliomyelitis Vaccine Sales, by Application K Units (2015-2020)
  • Table 217. Rest of Europe Poliomyelitis Vaccine Sales, by Route of Administration K Units (2015-2020)
  • Table 218. Rest of Europe Poliomyelitis Vaccine Sales, by Poliomyelitis Type K Units (2015-2020)
  • Table 219. MEA Poliomyelitis Vaccine Sales, by Country K Units (2015-2020)
  • Table 220. MEA Poliomyelitis Vaccine Sales, by Type K Units (2015-2020)
  • Table 221. MEA Poliomyelitis Vaccine Sales, by Application K Units (2015-2020)
  • Table 222. MEA Poliomyelitis Vaccine Sales, by Route of Administration K Units (2015-2020)
  • Table 223. MEA Poliomyelitis Vaccine Sales, by Poliomyelitis Type K Units (2015-2020)
  • Table 224. Middle East Poliomyelitis Vaccine Sales, by Type K Units (2015-2020)
  • Table 225. Middle East Poliomyelitis Vaccine Sales, by Application K Units (2015-2020)
  • Table 226. Middle East Poliomyelitis Vaccine Sales, by Route of Administration K Units (2015-2020)
  • Table 227. Middle East Poliomyelitis Vaccine Sales, by Poliomyelitis Type K Units (2015-2020)
  • Table 228. Africa Poliomyelitis Vaccine Sales, by Type K Units (2015-2020)
  • Table 229. Africa Poliomyelitis Vaccine Sales, by Application K Units (2015-2020)
  • Table 230. Africa Poliomyelitis Vaccine Sales, by Route of Administration K Units (2015-2020)
  • Table 231. Africa Poliomyelitis Vaccine Sales, by Poliomyelitis Type K Units (2015-2020)
  • Table 232. North America Poliomyelitis Vaccine Sales, by Country K Units (2015-2020)
  • Table 233. North America Poliomyelitis Vaccine Sales, by Type K Units (2015-2020)
  • Table 234. North America Poliomyelitis Vaccine Sales, by Application K Units (2015-2020)
  • Table 235. North America Poliomyelitis Vaccine Sales, by Route of Administration K Units (2015-2020)
  • Table 236. North America Poliomyelitis Vaccine Sales, by Poliomyelitis Type K Units (2015-2020)
  • Table 237. United States Poliomyelitis Vaccine Sales, by Type K Units (2015-2020)
  • Table 238. United States Poliomyelitis Vaccine Sales, by Application K Units (2015-2020)
  • Table 239. United States Poliomyelitis Vaccine Sales, by Route of Administration K Units (2015-2020)
  • Table 240. United States Poliomyelitis Vaccine Sales, by Poliomyelitis Type K Units (2015-2020)
  • Table 241. Canada Poliomyelitis Vaccine Sales, by Type K Units (2015-2020)
  • Table 242. Canada Poliomyelitis Vaccine Sales, by Application K Units (2015-2020)
  • Table 243. Canada Poliomyelitis Vaccine Sales, by Route of Administration K Units (2015-2020)
  • Table 244. Canada Poliomyelitis Vaccine Sales, by Poliomyelitis Type K Units (2015-2020)
  • Table 245. Mexico Poliomyelitis Vaccine Sales, by Type K Units (2015-2020)
  • Table 246. Mexico Poliomyelitis Vaccine Sales, by Application K Units (2015-2020)
  • Table 247. Mexico Poliomyelitis Vaccine Sales, by Route of Administration K Units (2015-2020)
  • Table 248. Mexico Poliomyelitis Vaccine Sales, by Poliomyelitis Type K Units (2015-2020)
  • Table 249. Poliomyelitis Vaccine: by Type(USD/Units)
  • Table 250. Company Basic Information, Sales Area and Its Competitors
  • Table 251. Company Basic Information, Sales Area and Its Competitors
  • Table 252. Company Basic Information, Sales Area and Its Competitors
  • Table 253. Company Basic Information, Sales Area and Its Competitors
  • Table 254. Company Basic Information, Sales Area and Its Competitors
  • Table 255. Company Basic Information, Sales Area and Its Competitors
  • Table 256. Company Basic Information, Sales Area and Its Competitors
  • Table 257. Company Basic Information, Sales Area and Its Competitors
  • Table 258. Company Basic Information, Sales Area and Its Competitors
  • Table 259. Company Basic Information, Sales Area and Its Competitors
  • Table 260. Company Basic Information, Sales Area and Its Competitors
  • Table 261. Poliomyelitis Vaccine: by Type(USD Million)
  • Table 262. Poliomyelitis Vaccine Oral Polio Vaccine (OPV) , by Region USD Million (2021-2026)
  • Table 263. Poliomyelitis Vaccine Inactivated Poliomyelitis Vaccine (IPV) , by Region USD Million (2021-2026)
  • Table 264. Poliomyelitis Vaccine: by Application(USD Million)
  • Table 265. Poliomyelitis Vaccine Hospital , by Region USD Million (2021-2026)
  • Table 266. Poliomyelitis Vaccine Clinics , by Region USD Million (2021-2026)
  • Table 267. Poliomyelitis Vaccine Public Services , by Region USD Million (2021-2026)
  • Table 268. Poliomyelitis Vaccine Others , by Region USD Million (2021-2026)
  • Table 269. Poliomyelitis Vaccine: by Route of Administration(USD Million)
  • Table 270. Poliomyelitis Vaccine Oral , by Region USD Million (2021-2026)
  • Table 271. Poliomyelitis Vaccine Injection , by Region USD Million (2021-2026)
  • Table 272. Poliomyelitis Vaccine: by Poliomyelitis Type(USD Million)
  • Table 273. Poliomyelitis Vaccine Type 1 , by Region USD Million (2021-2026)
  • Table 274. Poliomyelitis Vaccine Type 2 , by Region USD Million (2021-2026)
  • Table 275. Poliomyelitis Vaccine Type 3 , by Region USD Million (2021-2026)
  • Table 276. South America Poliomyelitis Vaccine, by Country USD Million (2021-2026)
  • Table 277. South America Poliomyelitis Vaccine, by Type USD Million (2021-2026)
  • Table 278. South America Poliomyelitis Vaccine, by Application USD Million (2021-2026)
  • Table 279. South America Poliomyelitis Vaccine, by Route of Administration USD Million (2021-2026)
  • Table 280. South America Poliomyelitis Vaccine, by Poliomyelitis Type USD Million (2021-2026)
  • Table 281. Brazil Poliomyelitis Vaccine, by Type USD Million (2021-2026)
  • Table 282. Brazil Poliomyelitis Vaccine, by Application USD Million (2021-2026)
  • Table 283. Brazil Poliomyelitis Vaccine, by Route of Administration USD Million (2021-2026)
  • Table 284. Brazil Poliomyelitis Vaccine, by Poliomyelitis Type USD Million (2021-2026)
  • Table 285. Argentina Poliomyelitis Vaccine, by Type USD Million (2021-2026)
  • Table 286. Argentina Poliomyelitis Vaccine, by Application USD Million (2021-2026)
  • Table 287. Argentina Poliomyelitis Vaccine, by Route of Administration USD Million (2021-2026)
  • Table 288. Argentina Poliomyelitis Vaccine, by Poliomyelitis Type USD Million (2021-2026)
  • Table 289. Rest of South America Poliomyelitis Vaccine, by Type USD Million (2021-2026)
  • Table 290. Rest of South America Poliomyelitis Vaccine, by Application USD Million (2021-2026)
  • Table 291. Rest of South America Poliomyelitis Vaccine, by Route of Administration USD Million (2021-2026)
  • Table 292. Rest of South America Poliomyelitis Vaccine, by Poliomyelitis Type USD Million (2021-2026)
  • Table 293. Asia Pacific Poliomyelitis Vaccine, by Country USD Million (2021-2026)
  • Table 294. Asia Pacific Poliomyelitis Vaccine, by Type USD Million (2021-2026)
  • Table 295. Asia Pacific Poliomyelitis Vaccine, by Application USD Million (2021-2026)
  • Table 296. Asia Pacific Poliomyelitis Vaccine, by Route of Administration USD Million (2021-2026)
  • Table 297. Asia Pacific Poliomyelitis Vaccine, by Poliomyelitis Type USD Million (2021-2026)
  • Table 298. China Poliomyelitis Vaccine, by Type USD Million (2021-2026)
  • Table 299. China Poliomyelitis Vaccine, by Application USD Million (2021-2026)
  • Table 300. China Poliomyelitis Vaccine, by Route of Administration USD Million (2021-2026)
  • Table 301. China Poliomyelitis Vaccine, by Poliomyelitis Type USD Million (2021-2026)
  • Table 302. Japan Poliomyelitis Vaccine, by Type USD Million (2021-2026)
  • Table 303. Japan Poliomyelitis Vaccine, by Application USD Million (2021-2026)
  • Table 304. Japan Poliomyelitis Vaccine, by Route of Administration USD Million (2021-2026)
  • Table 305. Japan Poliomyelitis Vaccine, by Poliomyelitis Type USD Million (2021-2026)
  • Table 306. India Poliomyelitis Vaccine, by Type USD Million (2021-2026)
  • Table 307. India Poliomyelitis Vaccine, by Application USD Million (2021-2026)
  • Table 308. India Poliomyelitis Vaccine, by Route of Administration USD Million (2021-2026)
  • Table 309. India Poliomyelitis Vaccine, by Poliomyelitis Type USD Million (2021-2026)
  • Table 310. South Korea Poliomyelitis Vaccine, by Type USD Million (2021-2026)
  • Table 311. South Korea Poliomyelitis Vaccine, by Application USD Million (2021-2026)
  • Table 312. South Korea Poliomyelitis Vaccine, by Route of Administration USD Million (2021-2026)
  • Table 313. South Korea Poliomyelitis Vaccine, by Poliomyelitis Type USD Million (2021-2026)
  • Table 314. Taiwan Poliomyelitis Vaccine, by Type USD Million (2021-2026)
  • Table 315. Taiwan Poliomyelitis Vaccine, by Application USD Million (2021-2026)
  • Table 316. Taiwan Poliomyelitis Vaccine, by Route of Administration USD Million (2021-2026)
  • Table 317. Taiwan Poliomyelitis Vaccine, by Poliomyelitis Type USD Million (2021-2026)
  • Table 318. Australia Poliomyelitis Vaccine, by Type USD Million (2021-2026)
  • Table 319. Australia Poliomyelitis Vaccine, by Application USD Million (2021-2026)
  • Table 320. Australia Poliomyelitis Vaccine, by Route of Administration USD Million (2021-2026)
  • Table 321. Australia Poliomyelitis Vaccine, by Poliomyelitis Type USD Million (2021-2026)
  • Table 322. Rest of Asia-Pacific Poliomyelitis Vaccine, by Type USD Million (2021-2026)
  • Table 323. Rest of Asia-Pacific Poliomyelitis Vaccine, by Application USD Million (2021-2026)
  • Table 324. Rest of Asia-Pacific Poliomyelitis Vaccine, by Route of Administration USD Million (2021-2026)
  • Table 325. Rest of Asia-Pacific Poliomyelitis Vaccine, by Poliomyelitis Type USD Million (2021-2026)
  • Table 326. Europe Poliomyelitis Vaccine, by Country USD Million (2021-2026)
  • Table 327. Europe Poliomyelitis Vaccine, by Type USD Million (2021-2026)
  • Table 328. Europe Poliomyelitis Vaccine, by Application USD Million (2021-2026)
  • Table 329. Europe Poliomyelitis Vaccine, by Route of Administration USD Million (2021-2026)
  • Table 330. Europe Poliomyelitis Vaccine, by Poliomyelitis Type USD Million (2021-2026)
  • Table 331. Germany Poliomyelitis Vaccine, by Type USD Million (2021-2026)
  • Table 332. Germany Poliomyelitis Vaccine, by Application USD Million (2021-2026)
  • Table 333. Germany Poliomyelitis Vaccine, by Route of Administration USD Million (2021-2026)
  • Table 334. Germany Poliomyelitis Vaccine, by Poliomyelitis Type USD Million (2021-2026)
  • Table 335. France Poliomyelitis Vaccine, by Type USD Million (2021-2026)
  • Table 336. France Poliomyelitis Vaccine, by Application USD Million (2021-2026)
  • Table 337. France Poliomyelitis Vaccine, by Route of Administration USD Million (2021-2026)
  • Table 338. France Poliomyelitis Vaccine, by Poliomyelitis Type USD Million (2021-2026)
  • Table 339. Italy Poliomyelitis Vaccine, by Type USD Million (2021-2026)
  • Table 340. Italy Poliomyelitis Vaccine, by Application USD Million (2021-2026)
  • Table 341. Italy Poliomyelitis Vaccine, by Route of Administration USD Million (2021-2026)
  • Table 342. Italy Poliomyelitis Vaccine, by Poliomyelitis Type USD Million (2021-2026)
  • Table 343. United Kingdom Poliomyelitis Vaccine, by Type USD Million (2021-2026)
  • Table 344. United Kingdom Poliomyelitis Vaccine, by Application USD Million (2021-2026)
  • Table 345. United Kingdom Poliomyelitis Vaccine, by Route of Administration USD Million (2021-2026)
  • Table 346. United Kingdom Poliomyelitis Vaccine, by Poliomyelitis Type USD Million (2021-2026)
  • Table 347. Netherlands Poliomyelitis Vaccine, by Type USD Million (2021-2026)
  • Table 348. Netherlands Poliomyelitis Vaccine, by Application USD Million (2021-2026)
  • Table 349. Netherlands Poliomyelitis Vaccine, by Route of Administration USD Million (2021-2026)
  • Table 350. Netherlands Poliomyelitis Vaccine, by Poliomyelitis Type USD Million (2021-2026)
  • Table 351. Rest of Europe Poliomyelitis Vaccine, by Type USD Million (2021-2026)
  • Table 352. Rest of Europe Poliomyelitis Vaccine, by Application USD Million (2021-2026)
  • Table 353. Rest of Europe Poliomyelitis Vaccine, by Route of Administration USD Million (2021-2026)
  • Table 354. Rest of Europe Poliomyelitis Vaccine, by Poliomyelitis Type USD Million (2021-2026)
  • Table 355. MEA Poliomyelitis Vaccine, by Country USD Million (2021-2026)
  • Table 356. MEA Poliomyelitis Vaccine, by Type USD Million (2021-2026)
  • Table 357. MEA Poliomyelitis Vaccine, by Application USD Million (2021-2026)
  • Table 358. MEA Poliomyelitis Vaccine, by Route of Administration USD Million (2021-2026)
  • Table 359. MEA Poliomyelitis Vaccine, by Poliomyelitis Type USD Million (2021-2026)
  • Table 360. Middle East Poliomyelitis Vaccine, by Type USD Million (2021-2026)
  • Table 361. Middle East Poliomyelitis Vaccine, by Application USD Million (2021-2026)
  • Table 362. Middle East Poliomyelitis Vaccine, by Route of Administration USD Million (2021-2026)
  • Table 363. Middle East Poliomyelitis Vaccine, by Poliomyelitis Type USD Million (2021-2026)
  • Table 364. Africa Poliomyelitis Vaccine, by Type USD Million (2021-2026)
  • Table 365. Africa Poliomyelitis Vaccine, by Application USD Million (2021-2026)
  • Table 366. Africa Poliomyelitis Vaccine, by Route of Administration USD Million (2021-2026)
  • Table 367. Africa Poliomyelitis Vaccine, by Poliomyelitis Type USD Million (2021-2026)
  • Table 368. North America Poliomyelitis Vaccine, by Country USD Million (2021-2026)
  • Table 369. North America Poliomyelitis Vaccine, by Type USD Million (2021-2026)
  • Table 370. North America Poliomyelitis Vaccine, by Application USD Million (2021-2026)
  • Table 371. North America Poliomyelitis Vaccine, by Route of Administration USD Million (2021-2026)
  • Table 372. North America Poliomyelitis Vaccine, by Poliomyelitis Type USD Million (2021-2026)
  • Table 373. United States Poliomyelitis Vaccine, by Type USD Million (2021-2026)
  • Table 374. United States Poliomyelitis Vaccine, by Application USD Million (2021-2026)
  • Table 375. United States Poliomyelitis Vaccine, by Route of Administration USD Million (2021-2026)
  • Table 376. United States Poliomyelitis Vaccine, by Poliomyelitis Type USD Million (2021-2026)
  • Table 377. Canada Poliomyelitis Vaccine, by Type USD Million (2021-2026)
  • Table 378. Canada Poliomyelitis Vaccine, by Application USD Million (2021-2026)
  • Table 379. Canada Poliomyelitis Vaccine, by Route of Administration USD Million (2021-2026)
  • Table 380. Canada Poliomyelitis Vaccine, by Poliomyelitis Type USD Million (2021-2026)
  • Table 381. Mexico Poliomyelitis Vaccine, by Type USD Million (2021-2026)
  • Table 382. Mexico Poliomyelitis Vaccine, by Application USD Million (2021-2026)
  • Table 383. Mexico Poliomyelitis Vaccine, by Route of Administration USD Million (2021-2026)
  • Table 384. Mexico Poliomyelitis Vaccine, by Poliomyelitis Type USD Million (2021-2026)
  • Table 385. Poliomyelitis Vaccine Sales: by Type(K Units)
  • Table 386. Poliomyelitis Vaccine Sales Oral Polio Vaccine (OPV) , by Region K Units (2021-2026)
  • Table 387. Poliomyelitis Vaccine Sales Inactivated Poliomyelitis Vaccine (IPV) , by Region K Units (2021-2026)
  • Table 388. Poliomyelitis Vaccine Sales: by Application(K Units)
  • Table 389. Poliomyelitis Vaccine Sales Hospital , by Region K Units (2021-2026)
  • Table 390. Poliomyelitis Vaccine Sales Clinics , by Region K Units (2021-2026)
  • Table 391. Poliomyelitis Vaccine Sales Public Services , by Region K Units (2021-2026)
  • Table 392. Poliomyelitis Vaccine Sales Others , by Region K Units (2021-2026)
  • Table 393. Poliomyelitis Vaccine Sales: by Route of Administration(K Units)
  • Table 394. Poliomyelitis Vaccine Sales Oral , by Region K Units (2021-2026)
  • Table 395. Poliomyelitis Vaccine Sales Injection , by Region K Units (2021-2026)
  • Table 396. Poliomyelitis Vaccine Sales: by Poliomyelitis Type(K Units)
  • Table 397. Poliomyelitis Vaccine Sales Type 1 , by Region K Units (2021-2026)
  • Table 398. Poliomyelitis Vaccine Sales Type 2 , by Region K Units (2021-2026)
  • Table 399. Poliomyelitis Vaccine Sales Type 3 , by Region K Units (2021-2026)
  • Table 400. South America Poliomyelitis Vaccine Sales, by Country K Units (2021-2026)
  • Table 401. South America Poliomyelitis Vaccine Sales, by Type K Units (2021-2026)
  • Table 402. South America Poliomyelitis Vaccine Sales, by Application K Units (2021-2026)
  • Table 403. South America Poliomyelitis Vaccine Sales, by Route of Administration K Units (2021-2026)
  • Table 404. South America Poliomyelitis Vaccine Sales, by Poliomyelitis Type K Units (2021-2026)
  • Table 405. Brazil Poliomyelitis Vaccine Sales, by Type K Units (2021-2026)
  • Table 406. Brazil Poliomyelitis Vaccine Sales, by Application K Units (2021-2026)
  • Table 407. Brazil Poliomyelitis Vaccine Sales, by Route of Administration K Units (2021-2026)
  • Table 408. Brazil Poliomyelitis Vaccine Sales, by Poliomyelitis Type K Units (2021-2026)
  • Table 409. Argentina Poliomyelitis Vaccine Sales, by Type K Units (2021-2026)
  • Table 410. Argentina Poliomyelitis Vaccine Sales, by Application K Units (2021-2026)
  • Table 411. Argentina Poliomyelitis Vaccine Sales, by Route of Administration K Units (2021-2026)
  • Table 412. Argentina Poliomyelitis Vaccine Sales, by Poliomyelitis Type K Units (2021-2026)
  • Table 413. Rest of South America Poliomyelitis Vaccine Sales, by Type K Units (2021-2026)
  • Table 414. Rest of South America Poliomyelitis Vaccine Sales, by Application K Units (2021-2026)
  • Table 415. Rest of South America Poliomyelitis Vaccine Sales, by Route of Administration K Units (2021-2026)
  • Table 416. Rest of South America Poliomyelitis Vaccine Sales, by Poliomyelitis Type K Units (2021-2026)
  • Table 417. Asia Pacific Poliomyelitis Vaccine Sales, by Country K Units (2021-2026)
  • Table 418. Asia Pacific Poliomyelitis Vaccine Sales, by Type K Units (2021-2026)
  • Table 419. Asia Pacific Poliomyelitis Vaccine Sales, by Application K Units (2021-2026)
  • Table 420. Asia Pacific Poliomyelitis Vaccine Sales, by Route of Administration K Units (2021-2026)
  • Table 421. Asia Pacific Poliomyelitis Vaccine Sales, by Poliomyelitis Type K Units (2021-2026)
  • Table 422. China Poliomyelitis Vaccine Sales, by Type K Units (2021-2026)
  • Table 423. China Poliomyelitis Vaccine Sales, by Application K Units (2021-2026)
  • Table 424. China Poliomyelitis Vaccine Sales, by Route of Administration K Units (2021-2026)
  • Table 425. China Poliomyelitis Vaccine Sales, by Poliomyelitis Type K Units (2021-2026)
  • Table 426. Japan Poliomyelitis Vaccine Sales, by Type K Units (2021-2026)
  • Table 427. Japan Poliomyelitis Vaccine Sales, by Application K Units (2021-2026)
  • Table 428. Japan Poliomyelitis Vaccine Sales, by Route of Administration K Units (2021-2026)
  • Table 429. Japan Poliomyelitis Vaccine Sales, by Poliomyelitis Type K Units (2021-2026)
  • Table 430. India Poliomyelitis Vaccine Sales, by Type K Units (2021-2026)
  • Table 431. India Poliomyelitis Vaccine Sales, by Application K Units (2021-2026)
  • Table 432. India Poliomyelitis Vaccine Sales, by Route of Administration K Units (2021-2026)
  • Table 433. India Poliomyelitis Vaccine Sales, by Poliomyelitis Type K Units (2021-2026)
  • Table 434. South Korea Poliomyelitis Vaccine Sales, by Type K Units (2021-2026)
  • Table 435. South Korea Poliomyelitis Vaccine Sales, by Application K Units (2021-2026)
  • Table 436. South Korea Poliomyelitis Vaccine Sales, by Route of Administration K Units (2021-2026)
  • Table 437. South Korea Poliomyelitis Vaccine Sales, by Poliomyelitis Type K Units (2021-2026)
  • Table 438. Taiwan Poliomyelitis Vaccine Sales, by Type K Units (2021-2026)
  • Table 439. Taiwan Poliomyelitis Vaccine Sales, by Application K Units (2021-2026)
  • Table 440. Taiwan Poliomyelitis Vaccine Sales, by Route of Administration K Units (2021-2026)
  • Table 441. Taiwan Poliomyelitis Vaccine Sales, by Poliomyelitis Type K Units (2021-2026)
  • Table 442. Australia Poliomyelitis Vaccine Sales, by Type K Units (2021-2026)
  • Table 443. Australia Poliomyelitis Vaccine Sales, by Application K Units (2021-2026)
  • Table 444. Australia Poliomyelitis Vaccine Sales, by Route of Administration K Units (2021-2026)
  • Table 445. Australia Poliomyelitis Vaccine Sales, by Poliomyelitis Type K Units (2021-2026)
  • Table 446. Rest of Asia-Pacific Poliomyelitis Vaccine Sales, by Type K Units (2021-2026)
  • Table 447. Rest of Asia-Pacific Poliomyelitis Vaccine Sales, by Application K Units (2021-2026)
  • Table 448. Rest of Asia-Pacific Poliomyelitis Vaccine Sales, by Route of Administration K Units (2021-2026)
  • Table 449. Rest of Asia-Pacific Poliomyelitis Vaccine Sales, by Poliomyelitis Type K Units (2021-2026)
  • Table 450. Europe Poliomyelitis Vaccine Sales, by Country K Units (2021-2026)
  • Table 451. Europe Poliomyelitis Vaccine Sales, by Type K Units (2021-2026)
  • Table 452. Europe Poliomyelitis Vaccine Sales, by Application K Units (2021-2026)
  • Table 453. Europe Poliomyelitis Vaccine Sales, by Route of Administration K Units (2021-2026)
  • Table 454. Europe Poliomyelitis Vaccine Sales, by Poliomyelitis Type K Units (2021-2026)
  • Table 455. Germany Poliomyelitis Vaccine Sales, by Type K Units (2021-2026)
  • Table 456. Germany Poliomyelitis Vaccine Sales, by Application K Units (2021-2026)
  • Table 457. Germany Poliomyelitis Vaccine Sales, by Route of Administration K Units (2021-2026)
  • Table 458. Germany Poliomyelitis Vaccine Sales, by Poliomyelitis Type K Units (2021-2026)
  • Table 459. France Poliomyelitis Vaccine Sales, by Type K Units (2021-2026)
  • Table 460. France Poliomyelitis Vaccine Sales, by Application K Units (2021-2026)
  • Table 461. France Poliomyelitis Vaccine Sales, by Route of Administration K Units (2021-2026)
  • Table 462. France Poliomyelitis Vaccine Sales, by Poliomyelitis Type K Units (2021-2026)
  • Table 463. Italy Poliomyelitis Vaccine Sales, by Type K Units (2021-2026)
  • Table 464. Italy Poliomyelitis Vaccine Sales, by Application K Units (2021-2026)
  • Table 465. Italy Poliomyelitis Vaccine Sales, by Route of Administration K Units (2021-2026)
  • Table 466. Italy Poliomyelitis Vaccine Sales, by Poliomyelitis Type K Units (2021-2026)
  • Table 467. United Kingdom Poliomyelitis Vaccine Sales, by Type K Units (2021-2026)
  • Table 468. United Kingdom Poliomyelitis Vaccine Sales, by Application K Units (2021-2026)
  • Table 469. United Kingdom Poliomyelitis Vaccine Sales, by Route of Administration K Units (2021-2026)
  • Table 470. United Kingdom Poliomyelitis Vaccine Sales, by Poliomyelitis Type K Units (2021-2026)
  • Table 471. Netherlands Poliomyelitis Vaccine Sales, by Type K Units (2021-2026)
  • Table 472. Netherlands Poliomyelitis Vaccine Sales, by Application K Units (2021-2026)
  • Table 473. Netherlands Poliomyelitis Vaccine Sales, by Route of Administration K Units (2021-2026)
  • Table 474. Netherlands Poliomyelitis Vaccine Sales, by Poliomyelitis Type K Units (2021-2026)
  • Table 475. Rest of Europe Poliomyelitis Vaccine Sales, by Type K Units (2021-2026)
  • Table 476. Rest of Europe Poliomyelitis Vaccine Sales, by Application K Units (2021-2026)
  • Table 477. Rest of Europe Poliomyelitis Vaccine Sales, by Route of Administration K Units (2021-2026)
  • Table 478. Rest of Europe Poliomyelitis Vaccine Sales, by Poliomyelitis Type K Units (2021-2026)
  • Table 479. MEA Poliomyelitis Vaccine Sales, by Country K Units (2021-2026)
  • Table 480. MEA Poliomyelitis Vaccine Sales, by Type K Units (2021-2026)
  • Table 481. MEA Poliomyelitis Vaccine Sales, by Application K Units (2021-2026)
  • Table 482. MEA Poliomyelitis Vaccine Sales, by Route of Administration K Units (2021-2026)
  • Table 483. MEA Poliomyelitis Vaccine Sales, by Poliomyelitis Type K Units (2021-2026)
  • Table 484. Middle East Poliomyelitis Vaccine Sales, by Type K Units (2021-2026)
  • Table 485. Middle East Poliomyelitis Vaccine Sales, by Application K Units (2021-2026)
  • Table 486. Middle East Poliomyelitis Vaccine Sales, by Route of Administration K Units (2021-2026)
  • Table 487. Middle East Poliomyelitis Vaccine Sales, by Poliomyelitis Type K Units (2021-2026)
  • Table 488. Africa Poliomyelitis Vaccine Sales, by Type K Units (2021-2026)
  • Table 489. Africa Poliomyelitis Vaccine Sales, by Application K Units (2021-2026)
  • Table 490. Africa Poliomyelitis Vaccine Sales, by Route of Administration K Units (2021-2026)
  • Table 491. Africa Poliomyelitis Vaccine Sales, by Poliomyelitis Type K Units (2021-2026)
  • Table 492. North America Poliomyelitis Vaccine Sales, by Country K Units (2021-2026)
  • Table 493. North America Poliomyelitis Vaccine Sales, by Type K Units (2021-2026)
  • Table 494. North America Poliomyelitis Vaccine Sales, by Application K Units (2021-2026)
  • Table 495. North America Poliomyelitis Vaccine Sales, by Route of Administration K Units (2021-2026)
  • Table 496. North America Poliomyelitis Vaccine Sales, by Poliomyelitis Type K Units (2021-2026)
  • Table 497. United States Poliomyelitis Vaccine Sales, by Type K Units (2021-2026)
  • Table 498. United States Poliomyelitis Vaccine Sales, by Application K Units (2021-2026)
  • Table 499. United States Poliomyelitis Vaccine Sales, by Route of Administration K Units (2021-2026)
  • Table 500. United States Poliomyelitis Vaccine Sales, by Poliomyelitis Type K Units (2021-2026)
  • Table 501. Canada Poliomyelitis Vaccine Sales, by Type K Units (2021-2026)
  • Table 502. Canada Poliomyelitis Vaccine Sales, by Application K Units (2021-2026)
  • Table 503. Canada Poliomyelitis Vaccine Sales, by Route of Administration K Units (2021-2026)
  • Table 504. Canada Poliomyelitis Vaccine Sales, by Poliomyelitis Type K Units (2021-2026)
  • Table 505. Mexico Poliomyelitis Vaccine Sales, by Type K Units (2021-2026)
  • Table 506. Mexico Poliomyelitis Vaccine Sales, by Application K Units (2021-2026)
  • Table 507. Mexico Poliomyelitis Vaccine Sales, by Route of Administration K Units (2021-2026)
  • Table 508. Mexico Poliomyelitis Vaccine Sales, by Poliomyelitis Type K Units (2021-2026)
  • Table 509. Poliomyelitis Vaccine: by Type(USD/Units)
  • Table 510. Research Programs/Design for This Report
  • Table 511. Key Data Information from Secondary Sources
  • Table 512. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Poliomyelitis Vaccine: by Type USD Million (2015-2020)
  • Figure 5. Global Poliomyelitis Vaccine: by Application USD Million (2015-2020)
  • Figure 6. Global Poliomyelitis Vaccine: by Route of Administration USD Million (2015-2020)
  • Figure 7. Global Poliomyelitis Vaccine: by Poliomyelitis Type USD Million (2015-2020)
  • Figure 8. South America Poliomyelitis Vaccine Share (%), by Country
  • Figure 9. Asia Pacific Poliomyelitis Vaccine Share (%), by Country
  • Figure 10. Europe Poliomyelitis Vaccine Share (%), by Country
  • Figure 11. MEA Poliomyelitis Vaccine Share (%), by Country
  • Figure 12. North America Poliomyelitis Vaccine Share (%), by Country
  • Figure 13. Global Poliomyelitis Vaccine: by Type K Units (2015-2020)
  • Figure 14. Global Poliomyelitis Vaccine: by Application K Units (2015-2020)
  • Figure 15. Global Poliomyelitis Vaccine: by Route of Administration K Units (2015-2020)
  • Figure 16. Global Poliomyelitis Vaccine: by Poliomyelitis Type K Units (2015-2020)
  • Figure 17. South America Poliomyelitis Vaccine Share (%), by Country
  • Figure 18. Asia Pacific Poliomyelitis Vaccine Share (%), by Country
  • Figure 19. Europe Poliomyelitis Vaccine Share (%), by Country
  • Figure 20. MEA Poliomyelitis Vaccine Share (%), by Country
  • Figure 21. North America Poliomyelitis Vaccine Share (%), by Country
  • Figure 22. Global Poliomyelitis Vaccine: by Type USD/Units (2015-2020)
  • Figure 23. Global Poliomyelitis Vaccine share by Players 2020 (%)
  • Figure 24. Global Poliomyelitis Vaccine share by Players (Top 3) 2020(%)
  • Figure 25. Global Poliomyelitis Vaccine share by Players (Top 5) 2020(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 28. Sanofi (France) Revenue: by Geography 2020
  • Figure 29. GSK (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 30. GSK (United Kingdom) Revenue: by Geography 2020
  • Figure 31. Bibcol (India) Revenue, Net Income and Gross profit
  • Figure 32. Bibcol (India) Revenue: by Geography 2020
  • Figure 33. Crucell (Johnson & Johnson) (Netherlands) Revenue, Net Income and Gross profit
  • Figure 34. Crucell (Johnson & Johnson) (Netherlands) Revenue: by Geography 2020
  • Figure 35. Serum Institute (India) Revenue, Net Income and Gross profit
  • Figure 36. Serum Institute (India) Revenue: by Geography 2020
  • Figure 37. Merck & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 38. Merck & Co. (United States) Revenue: by Geography 2020
  • Figure 39. Tiantan Biological (China) Revenue, Net Income and Gross profit
  • Figure 40. Tiantan Biological (China) Revenue: by Geography 2020
  • Figure 41. Panacea Biotec Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 42. Panacea Biotec Ltd. (India) Revenue: by Geography 2020
  • Figure 43. Bio-Med (India) Revenue, Net Income and Gross profit
  • Figure 44. Bio-Med (India) Revenue: by Geography 2020
  • Figure 45. Halfkin Bio-Pharmaceuticals Corporation Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 46. Halfkin Bio-Pharmaceuticals Corporation Ltd. (India) Revenue: by Geography 2020
  • Figure 47. China National Biotech Group (China) Revenue, Net Income and Gross profit
  • Figure 48. China National Biotech Group (China) Revenue: by Geography 2020
  • Figure 49. Global Poliomyelitis Vaccine: by Type USD Million (2021-2026)
  • Figure 50. Global Poliomyelitis Vaccine: by Application USD Million (2021-2026)
  • Figure 51. Global Poliomyelitis Vaccine: by Route of Administration USD Million (2021-2026)
  • Figure 52. Global Poliomyelitis Vaccine: by Poliomyelitis Type USD Million (2021-2026)
  • Figure 53. South America Poliomyelitis Vaccine Share (%), by Country
  • Figure 54. Asia Pacific Poliomyelitis Vaccine Share (%), by Country
  • Figure 55. Europe Poliomyelitis Vaccine Share (%), by Country
  • Figure 56. MEA Poliomyelitis Vaccine Share (%), by Country
  • Figure 57. North America Poliomyelitis Vaccine Share (%), by Country
  • Figure 58. Global Poliomyelitis Vaccine: by Type K Units (2021-2026)
  • Figure 59. Global Poliomyelitis Vaccine: by Application K Units (2021-2026)
  • Figure 60. Global Poliomyelitis Vaccine: by Route of Administration K Units (2021-2026)
  • Figure 61. Global Poliomyelitis Vaccine: by Poliomyelitis Type K Units (2021-2026)
  • Figure 62. South America Poliomyelitis Vaccine Share (%), by Country
  • Figure 63. Asia Pacific Poliomyelitis Vaccine Share (%), by Country
  • Figure 64. Europe Poliomyelitis Vaccine Share (%), by Country
  • Figure 65. MEA Poliomyelitis Vaccine Share (%), by Country
  • Figure 66. North America Poliomyelitis Vaccine Share (%), by Country
  • Figure 67. Global Poliomyelitis Vaccine: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • Sanofi (France)
  • GSK (United Kingdom)
  • Bibcol (India)
  • Crucell (Johnson & Johnson) (Netherlands)
  • Serum Institute (India)
  • Merck & Co. (United States)
  • Tiantan Biological (China)
  • Panacea Biotec Ltd. (India)
  • Bio-Med (India)
  • Halfkin Bio-Pharmaceuticals Corporation Ltd. (India)
  • China National Biotech Group (China)
Select User Access Type

Key Highlights of Report


Feb 2021 211 Pages 65 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Poliomyelitis Vaccine research Quantitative research analysis
Global Poliomyelitis Vaccine research Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Global Poliomyelitis Vaccine market is expected to see a growth of % during projected year 2020 to 2026.
The prominent players of Global Poliomyelitis Vaccine market are Sanofi (France), GSK (United Kingdom), Bibcol (India), Crucell (Johnson & Johnson) (Netherlands), Serum Institute (India), Merck & Co. (United States), Tiantan Biological (China), Panacea Biotec Ltd. (India), Bio-Med (India), Halfkin Bio-Pharmaceuticals Corporation Ltd. (India) and China National Biotech Group (China), to name a few.
In this highly competitive & fast evolving Poliomyelitis Vaccine industry, the top strategic priorities would remain consistent like innovation, R&D and M&A.

Know More About Global Poliomyelitis Vaccine research Report?

Have a Query? Click Here

Other Related Reports

Measles Vaccine Comprehensive Study by Type (Mumps Measles Rubella Vaccine, Live (MMR-II), Mumps Measles Rubella and Varicella Virus Vaccine (Proquad)), Application (Pediatric Vaccines, Adult Vaccine...
$ 3450
Meningococcal Vaccines Comprehensive Study by Type (Polysaccharide Vaccines, Conjugate Vaccines, Combination Vaccines, Others), Application (Pneumonia, Meningitis, Bacteremia, Others (Arthritis, Conj...
$ 3750
Asthma Treatment Drugs Comprehensive Study by Type (Long-term Control Medications, Quick-relief Medications (Rescue Medications), Medications for Allergy-induced Asthma), Application (Hospital Pharma...
$ 3750
Nevirapine Comprehensive Study by Type (100 mg, 200 mg, 400 mg), Application (Women (Pregnant, Non- pregnant), Men), Method (Antiretroviral Therapy, Hepatotoxicity) Players and Region - Global Market...
$ 3500
Medication Adherence Packaging Systems Comprehensive Study by Type (Unit-dose Packaging Systems, Multi-dose Packaging Systems), Packaging (Ampoules, Vials, Prefilled Syringes & Injectable, Blisters, ...
$ 3750
Osteoarthritis Pain Drugs Comprehensive Study by Type (Oral, Injection, External), Application (Medical Care, Personal Care), Therapies (Non- Pharmacological Therapy, Pharmacological Therapy, Surgica...
$ 3750